FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company's first commercial product, AC5® Advanced Wound System ("AC5"), will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting ("SAWC Fall"), which takes place at Caesars Palace, Las Vegas, from November 2-5, 2023.
On Saturday, November 4, 2023, the following clinical case, which further demonstrates the use of AC5 in patients with chronic and non-healing wounds, will be presented during the poster viewing session.
Use of an Innovative Synthetic Self-Assembling Peptide Matrix in the Treatment of Three Large Recalcitrant 20-Year Old Venous Leg Ulcers–A Case Study
by Misael Alonso, MD, FACP, CWSP, FAPWCA (Goodyear, Arizona)
Poster #: CS-006
On Sunday, November 5, 2023 from 9:10 A.M. EST – 11:20 A.M. EST, AC5 will be featured in the Advanced Wound Care Therapy for the Lower Extremity: Hands-On Skills Lab. In this demonstration workshop, attending clinicians will be provided both hands-on experience with AC5 and an opportunity to learn about its mechanism, preparation, application, and utility in various wound types.
Arch's commercial team and senior medical science liaison will be available for discussions with clinicians throughout the symposium and at Arch's booth (#332) in the exhibit hall.
Terrence W. Norchi, MD, President and CEO of Arch Therapeutics said, "SAWC presents an important opportunity to showcase our proprietary self-assembling peptide technology to wound care providers. The case study highlights yet another person with a challenging wound that responded to AC5 after repeated and prolonged failure of other treatment regimens, while the skills lab demonstrations will give wound care providers a chance to learn ...